IAG . Bankinter Fija su Precio Objetivo en 3,50€ Por Acción . En Marcha la Recompra de Acciones .
07 diciembre 2009
ASH : Results of a cost analysis that compared multiple myeloma treatments found that treatment with bortezomib (Velcade) ...
... was associated with less out-of-pocket expenses than was treatment with the oral medications lenolidomide (Revlimid) and thalidomide (Thalomid).
...
‹
›
Inicio
Ver versión web